Research programme: pain therapeutics - Impel Pharmaceuticals
Alternative Names: INP-106Latest Information Update: 27 Apr 2022
At a glance
- Originator Impel NeuroPharma
- Developer Impel Pharmaceuticals
- Class Analgesics; Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pain
Most Recent Events
- 25 Apr 2022 Impel Neuropharma is now called Impel Pharmaceuticals
- 09 Feb 2018 No development reported - Preclinical for Pain in USA (Intranasal) (Impel NeuroPharma website, February 2018)
- 15 Dec 2016 Preclinical trials in Pain in USA (Intranasal) before December 2016